for the Digiday Programmatic Marketing Summit, May 6-8 in Palm Springs.
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
How did Nike’s embattled heritage brand Converse reach a 15-year revenue low?
The last few years have seen Converse continue to underperform compared to the rest of Nike’s portfolio.
Why Pfizer and other blue-chip brands are building internal AI search hubs to reclaim control
As AI upends traditional rankings, big spenders like Pfizer and other blue-chip brands are building internal task forces.
OpenAI has quietly launched its ads manager as it races to build out its ads business
The AI platform quietly launched its ads manager within its ChatGPT ads pilot advertisers last week, and also lowered the barrier to joining the test.